CMN Weekly (8 November 2024) - Your Weekly CRISPR...
CMN Weekly
Nov. 8, 2024
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc.
Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated
Sponsors:
Vertex Pharmaceuticals Incorporated
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04208529)
Sponsors:
Vertex Pharmaceuticals
Sponsors:
Vertex Pharmaceuticals
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
